Chiu Chia-Yu, Chastain Daniel B, Salam Madison E, Sassine Joseph, Henao-Martínez Andrés F
Department of Medicine, Division of Infectious Diseases, University of Colorado, Aurora, Colorado, USA.
Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Albany, Georgia, USA.
Antimicrob Agents Chemother. 2025 Apr 2;69(4):e0192424. doi: 10.1128/aac.01924-24. Epub 2025 Mar 4.
Fidaxomicin may exhibit cross-reactivity in patients with known macrolide allergies. In this analysis, compared to patients without macrolide allergies, the odds of fidaxomicin allergy were 2.31, 8.37, and 1.58 times higher in patients with azithromycin, clarithromycin, and erythromycin allergies, respectively; the absolute risk of fidaxomicin allergy was 0.033, 0.01, and 0.039 in patients with azithromycin, clarithromycin, and erythromycin allergies, respectively. The highest risk of anaphylaxis and angioedema was observed within 1 year of a non-fidaxomicin macrolide allergy.
非达霉素可能在已知大环内酯类过敏的患者中表现出交叉反应性。在该分析中，与无大环内酯类过敏的患者相比，阿奇霉素、克拉霉素和红霉素过敏的患者出现非达霉素过敏的几率分别高2.31倍、8.37倍和1.58倍；阿奇霉素、克拉霉素和红霉素过敏的患者出现非达霉素过敏的绝对风险分别为0.033、0.01和0.039。在非达霉素大环内酯类过敏后1年内观察到过敏反应和血管性水肿的最高风险。
